Thermo Fisher Scientific and CSL Enter Strategic Partnership to Provide Best-in-Class Pharma Services
To enhance our offering with expanded capabilities in order to meet the growing demand for biologic therapies, Thermo Fisher Scientific and global biotechnology company, CSL announced they have entered into a strategic partnership to help meet the growing demand for biologic therapies. Thermo Fisher will support CSL’s product portfolio by leveraging its pharma services network, including drug product development, biologics manufacturing, sterile fill-finish, packaging and clinical trials logistics. Additionally, through a long-term lease agreement with CSL, Thermo Fisher will operate a new state-of-the-art biologics manufacturing facility in Lengnau, Switzerland.
Thermo Fisher Scientific is closely monitoring the COVID-19 situation as it continues to evolve. The health and safety of our employees and our ability to ensure the delivery of medicines to patients is our top priority. Click Here for our latest business updates.
Thermo Fisher Scientific Doubles Capacity to Produce Cell & Gene Therapies
To support increasing demand for viral vector development and manufacturing services, we are expanding capacity with construction of a new commercial manufacturing site in Plainville, Mass. The 290,000-square-foot facility will more than double our commercial viral vector capacity to support customers who are developing and manufacturing gene therapies and vaccines to address unmet medical needs.
Case Study: Kaleido Biosciences Successfully Meets Aggressive IND Filing
Designed specifically for new and emerging companies such as Kaleido Biosciences, The Quick to Care™ program is an integrated solution that combines drug substance and drug product development, clinical manufacturing, forecasting, demand planning and clinical trial supply execution managed by a single program manager. Learn how Kaleido Biosciences was able to simplify their supply chain to meet their aggressive timeline with the Quick to Care™ program.
The Patheon brand is expanding to include viral vector services and clinical trial solutions
Our CDMO and clinical services offerings are now unified under the Patheon brand. Learn more about our full breadth of capabilities for pharma and biotech companies of all sizes, and how we can take your discovery from clinical to commercial.
